SHANK2 and cancer: During EMT, PRMT7 methylates the scaffolding protein SH3 and multiple ankyrin repeat domain 2 (SHANK2) and activates endosomal focal adhesion kinase/cortactin signaling, contributing to cancer cell invasion, metastasis, and malignancy [12].